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ABSTRACT
Fabry disease (FD) is an X-linked disorder of glycosphingo-
lipid catabolism resulting in the accumulation of glycolipids
including globotriaosylceramide in cells of various tissues
resulting in end-organ manifestations. Initially, FD is typi-
cally characterized by angiokeratoma and recurrent episodes
of neuropathic pain in the extremities occurring during
childhood or adolescence. Most affected patients also exhibit
a decreased ability to sweat. Later in life, FD results in left
ventricular hypertrophy, proteinuria, renal failure and
stroke. These later disease manifestations are non-speciﬁc
and also common in diabetes, hypertension and atheroma-
tosis and thus for most practitioners do not point into the
direction of FD. As a consequence, FD is under-diagnosed
and screening of high-risk groups is important for case
ﬁnding, as is a thorough pedigree analysis of affected
patients. In the nephrology clinic, we suggest to screen
patients for FD when there is unexplained chronic kidney
disease in males younger than 50 years and females of any
age. In men, this can be performed by measuring α-galacto-
sidase A activity in plasma, white blood cells or dried blood
spots. In women, mutation analysis is necessary, as enzyme
measurement alone could miss over one-third of female
Fabry patients. A multidisciplinary team should closely
monitor all known Fabry patients, with the nephrologist
screening kidney impairment (glomerular ﬁltration rate and
proteinuria) on a regular basis. Transplanted Fabry patients
have a higher mortality than the regular transplant popu-
lation, but have acceptable outcomes, compared with Fabry
patients remaining on dialysis. It is unclear whether enzyme
replacement therapy (ERT) prevents deterioration of kidney
function. In view of the lack of compelling evidence for
ERT, and the low likelihood that a sufﬁciently powered ran-
domized controlled trial on this topic will be performed,
data of all patients with FD should be collected in a central
registry.
© The Author 2012. Published by Oxford University Press on
behalf of ERA-EDTA. All rights reserved.
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INTRODUCTION
European Renal Best Practice (ERBP) is the ofﬁcial guideline
body of the European Renal Association/European Dialysis
and Transplant Association (ERA/EDTA). The mission of
ERBP is to improve the outcome of patients with kidney
disease in a sustainable way, through enhancing the accessi-
bility of knowledge on patient care, in a format that stimu-
lates its use in clinical practice. In line with this mission, and
in view of its philosophy [1], the ERBP advisory board con-
sidered it useful to develop guidance in the ﬁeld of orphan
diseases with nephrological relevance. Typical for these dis-
eases are the rather low patient number, and consequently,
the lack of large trials. As a consequence, formal evidence-
based medicine is nearly impossible in this ﬁeld. Neverthe-
less, nephrologists need guidance on how to approach
patients with these diseases. Therefore, ERBP decided to use
the combination of formal systematic literature reviews, a
consensus meeting with an international panel of experts and
peer review as a suitable model to develop guidance in the
ﬁeld of orphan diseases. A ﬁrst paper on oxalosis has already
been published in this series [2]. This paper presents the
results of a guidance process on the topic of Fabry disease
(FD).
FD (OMIM ID #301500) is an X-linked inborn error of
glycosphingolipid catabolism caused by quantitative or quali-
tative defects in the lysosomal enzyme α-galactosidase A (α-
Gal A). As a result, glycosphingolipids, mainly globotriaosyl-
ceramide (Gb-3), accumulate in the lysosomes of different
cells throughout the body, ultimately resulting in organ
failure [3, 4]. Patients with FD have a markedly limited life
expectancy due to cardiovascular, neurological and renal in-
volvement. Enzyme replacement therapy (ERT) has been
made available since 2001. Intravenous infusion every other
week results in the removal of a part of the Gb-3 deposits,
diminishes Fabry-related symptoms and possibly protects
organs to a certain extent [5, 6]. The effects of ERT on pro-
gression of renal disease (proteinuria and renal function) are
unclear.
AIMS OF THIS PUBLICATION
The ﬁrst aim of this paper is to review the current literature
on renal disease in Fabry patients, in order to provide gui-
dance to the nephrologist on when to screen for this disease
and why, and to understand the preferred methods that
should be used for screening.
The second aim is to provide guidance on the follow-up,
prevention and treatment of renal disease, and its compli-
cations (proteinuria, renal failure). The role of ERT, angio-
tensin-converting enzyme inhibitors (ACEi), angiotensin
receptor blockers (ARB) and renal replacement therapy
(RRT) is reviewed.
METHODS
A literature search was conducted using the PubMed database
(most recent search July 2012). The search term used was
‘Fabry Disease’ with limits: ‘Humans’, ‘Clinical Trial’, ‘Meta-
Analysis’, ‘Practice Guideline’, ‘Randomized Controlled Trial’,
‘Review’, ‘English’, ‘French’. A total of 357 articles were re-
trieved; the articles were classiﬁed to the following topics
(one paper can be attributed to more than one classiﬁcation):
(i) epidemiology, screening studies;
(ii) diagnostic methods;
(iii) Fabry nephropathy: natural history, complications (hy-
pertension), mechanisms, renal pathology;
(iv) treatment of Fabry nephropathy; with ERT, ACEi and
ARB, RRT; efﬁcacy and safety issues.
Articles out of scope and review articles that presented no
new data were excluded. Articles on experimental, non-regis-
tered treatments were also excluded.
The reference lists of the identiﬁed relevant studies were
manually searched for additional citations.
After all relevant publications were retrieved, a consensus
meeting was held with all co-authors. The resulting paper was
sent for internal review before submission, as explained in
the ‘instructions to authors’ section of the ERBP website [7].
EPIDEMIOLOGY AND THE NEED FOR
SCREENING
1.1 We do not recommend screening in the general popu-
lation. (Ungraded statement)
1.2 We recommend obtaining informed consent from the
patient before screening, using an information form
drafted in collaboration with a clinical geneticist. (Un-
graded statement)
1.3 We recommend screening for FD in male chronic kidney
disease (CKD) patients below 50 years of age in whom a
reliable renal diagnosis is absent. (Ungraded statement)
1.4 We suggest screening for FD in females with unexplained
CKD, irrespective of age, with other unexplained symp-
toms potentially associated with FD. (Ungraded statement)
1.5 We recommend discussing with the patient the impli-
cations of diagnosing a genetic disease and the possible
implications for the at-risk relatives. (Level 1C)
Rationale
Classical FD is a progressive multisystem disease predomi-
nantly presenting in males, characterized by angiokeratoma,
hypohidrosis and acroparesthesia (neuropathic pain) in child-
hood, followed by renal failure, left ventricular hypertrophy
(LVH), stroke and premature death in the fourth or ﬁfth
decade of life [8]. In male patients, levels of α-Gal A activity
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are classically very low or undetectable. However, as a result
of screening studies during the past decade, clinical variants
of FD in male patients with varying degrees of residual
activity of α-Gal A have been described. The ﬁrst described
was the ‘cardiac variant’ with isolated LVH and/or cardio-
myopathy presenting in the sixth or seventh decade, lacking
the classical disease symptoms and time course [9, 10].
Patients suffering from this variant may have proteinuria, but
their renal function is typically normal for their age. Later a
‘renal variant’ phenotype was described in a screening study
in a dialysis population, where patients again were lacking the
classical manifestations. This phenotype was described as
‘intermediate’ between the cardiac variant and the classic
phenotype [11]. These patients with cardiac and renal var-
iants are called ‘atypical’ or ‘attenuated’ FD patients. The
genetic basis of this variable penetrance and expression is
unclear. It is believed that the atypical cases are the result of
missense mutations that encode mutant enzyme protein or
intronic lesions that reduce transcript levels, both resulting in
a reduced but signiﬁcant residual enzyme function (1–12% of
normal) [12], although this has been debated, and others
found no genotype–phenotype correlation [13]. Heterozygous
women, in spite of having a mutation compatible with typical
disease, can also present this attenuated phenotype as it was
hypothesized that skewed X-inactivation can result in signiﬁ-
cant residual enzyme function. However, it must be stressed
that most females have the classical phenotype, but with a
delayed and/or milder presentation of symptoms [14].
As a consequence, reported prevalence varies with the popu-
lation studied and the test used for screening, and genetic screen-
ing might ﬁnd female index cases that are not found by enzyme-
based methods [15]. The prevalence of classical FD has been es-
timated at 1 in 117 000 births [14] and 1 in 40 000 males [8]. In
several screening studies in high-risk populations, the frequency
was up to 1% or even higher, especially in populations with un-
explained LVH [16]. In newborns [17–19], the incidence of α-
Gal A deﬁciency was 1 in 3100 with an 11 to 1 ratio of patients
with the later-onset versus the classic phenotype. In the haemo-
dialysis population, a prevalence of 0.33% in male and 0.10% in
female patients has been found in a cross-sectional screening
study [16]. Only two studies screened kidney transplant patients.
In cryptogenic stroke, a prevalence of 0.8% [20] up to 2.4% [21]
and 3.9% [22] was found; however, in the second study [21],
half of the patients had the p.D313Y mutation, which is now
generally regarded as a pseudo-deﬁciency, and in the last study
[22], the speciﬁc mutations were not mentioned and could also
have been polymorphisms. Many screening studies are not con-
clusive for the female population, as they most frequently used
α-Gal A activity screening, which is in women, as described
above, not a sensitive screening tool.
Although there are no studies in the CKD population not
on dialysis, we recommend screening for FD in patients with
CKD without a clear diagnosis. In classical FD, most males
reach CKD Stage 5 or die before the age of 50 [12, 23]. As a
consequence, we recommend screening in males only below
the age of 50 years. We recommend screening even in the
case of a negative family history as de novo mutations can
occur, and the family history is not always suggestive for FD,
given the broad phenotypic spectrum of the disease. Arterial
hypertension should not be an exclusion criterion as more
than 50% of FD patients have mild to moderate hypertension,
especially when estimated glomerular ﬁltration rate (eGFR) is
<60 mL/min/1.73 m2 [23–25]. In women, disease onset can
be later, so when there is unexplained kidney disease associ-
ated with manifestations suggestive of FD, we suggest screen-
ing for FD regardless of age.
The real prevalence should be derived from screening in
the healthy population at a young age; this has been done in
four studies in newborns [17–19, 26]. However, this approach
remains problematic for several reasons. The American
College of Medical Genetics (ACMG) has proposed newborn
screening for 29 disorders, but screening for FD was not in-
cluded in this list (available online at: http://mchb.hrsa.gov/
screening/). Although measurement of α-Gal A has a good
sensitivity and speciﬁcity in males, it has a low positive pre-
dictive value in the healthy population. This will result in
unnecessary expensive tests. In addition, the majority of the
detected cases in the newborn studies are ‘atypical’ mutations,
giving an attenuated phenotype or a cardiac variant. The
ﬁnding of a genetic predisposition for a possible late-onset
disease where the treatment effectiveness is unclear has
ethical and legal implications that constrain a systematic
screening of newborns. In these cases, it would be difﬁcult to
decide on ERT, as the natural history of patients carrying aty-
pical mutations is poorly characterized, effects of ERT in
mild cases have not been studied, and a lifelong treatment is
a psychological burden for the patient and a ﬁnancial one for
both the individual and society with, on top of that, uncertain
results. As a consequence, we do not recommend screening
for FD in the general population.
As FD is an X-linked disease with variable but signiﬁcant
morbidity both in males and females, its diagnosis might
have profound consequences for the proband and his rela-
tives. As a consequence, we recommend obtaining informed
consent from the proband before screening, when possible in
cooperation with an expert in genetic counselling. (Example
in Supplementary appendix.)
Once the diagnosis is made, it is important to make up a
pedigree in order to identify all relatives at risk. FD is an X-
linked disease where all carriers can be symptomatic. It
should be kept in mind that ‘skipping’ of a generation is
possible because of variable expression.
The patient should receive further guidance in communi-
cation with his family. He must be able to provide sufﬁcient
information (e.g. by using ﬂyers written by the treating
team), and one must anticipate a number of possible pro-
blems in the communication with his family. Some people do
not want a work-up to the diagnosis of FD, and it should be
explained to the patient that they do have the right not to
know their genetic status.
SCREENING METHODS
2.1 We recommend using enzyme activity measurement for
α-Gal A as a primary tool in males, followed by
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conﬁrmation with mutation analysis when positive. (Un-
graded statement)
2.2 We suggest using mutation analysis as a primary tool for
screening in females. (Ungraded statement)
Measurement of α-Gal A activity in leucocytes using the ﬂuoro-
genic substrate 4-methylumbelliferyl-α-D-galactopyranoside is
the gold standard for FD in men, with a sensitivity and speci-
ﬁcity of nearly 100%. Recently, a dried blood spot test (DBS)
using ﬁlter paper has been proposed as an alternative to the leu-
cocyte tests [27]. These samples are easy to transport and are
stable at room temperature for many days, making it a most
convenient screening tool in men, as it is a very sensitive tool
with a negative predictive value reaching 100%.
In women, due to skewed X inactivation, enzyme activity
measurement has a low sensitivity, as one in three women
with FD have normal or nearly normal α-Gal A activity [15].
For this reason, enzymatic tests are less suitable and systema-
tic genetic testing should be encouraged in females with un-
explained CKD and manifestations suggestive for FD. As
genetic testing is expensive (150–1000 Euro and more per
test), a thorough anamnesis, family history and clinical inves-
tigation could help to select female CKD patients in whom
testing is cost-effective (Figure 1).
In FD, gene mutation analysis is a way of conﬁrming diag-
nosis in male patients, subsequent to enzyme activity
measurement. A fresh blood sample can be collected for this
purpose, or polymerase chain reaction ampliﬁcation can be
performed on DNA eluted directly from the ﬁlter paper used
for the DBS α-Gal A measurement [28].
GLA gene mutations causing FD include single base
changes leading to missense or nonsense mutations, or affect-
ing consensus splice sites, small deletions or insertions, but
also large gene rearrangements in <5% of the patients. Corre-
lations between a speciﬁc mutation, i.e. the genotype, and the
severity of the disease, the phenotype, are poor in FD. In a
few cases, however, knowledge on the underlying mutation
can provide information concerning prognosis and therapy
and help the clinician in counselling. Some mutations are fre-
quently associated with an attenuated phenotype, such as the
mutation p.N215S, which gives a cardiac phenotype with
only LVH [29]. These mutations are associated with a
residual enzyme function [30]. A signiﬁcant proportion of
the mutations in men are, however, associated with a very
low or absent enzyme function and the classic phenotype.
The GLA gene should be sequenced. As most of the
mutations are ‘private’, i.e. unique to a family, it is always
possible to completely identify a previously undetected
mutation, and regular updates of such new mutations are
available (http://www.hgmd.cf.ac.uk/ac/index.php). The
pathogenicity of novel gene alterations such as missense or
intronic mutations must always be evaluated. However, in
females with normal biochemical tests, it may be difﬁcult to
conﬁrm or exclude the diagnosis of FD when a variant of
unknown signiﬁcance is present.
In a suggestive clinical situation, most sequence alterations
in exonic regions are pathogenic with very few exceptions.
One example of such inert exonic polymorphism is the
p. ‘D313Y’ substitution (G to T at cDNA nucleotide 937);
while the plasma enzyme activity towards the artiﬁcial sub-
strate is signiﬁcantly reduced, additional studies demonstrated
high residual lysosomal enzyme activity and no pathologic
excretion of urinary Gb-3. As a result, the p.D313Y substi-
tution is now generally considered to be a so-called pseudo-
deﬁciency.
If one ﬁnds a novel sequence variation in an intronic
region or a novel missense mutation that is not known to be
a polymorphism present in the general population, several
methods allow non-invasive diagnostic analysis to establish
whether it is disease causing. First, it should be checked
whether these sequence variations exist in the normal popu-
lation (using electronic databases or an own control popu-
lation). The second step is to check male relatives of the
index case who are carriers of the sequence variation for α- A
activity. If the sequence variation is present in some of them,
despite a normal α-Gal A activity and absence of clinical
manifestations of FD, the sequence variation can be con-
sidered to be a polymorphism. If it coincides with a deﬁcient
α-Gal A in one or more of the male relatives, the possibility
of a disease causing mutation is realistic, and in this case, a
work-up of all carriers for the presence of (subclinical) FD
disease manifestations should be considered.
Besides enzyme activity measurement and mutation analy-
sis, detection of the accumulating substances (glycosphingoli-
pids) has been studied as a tool for diagnosis.
Globotriaosylceramide (Gb-3) is the most important glyco-
sphingolipid, and it should be measured in urine rather than
in plasma. Urinary Gb-3 can be a useful diagnostic tool in
female heterozygotes with classical FD as it is increased in
95% of them. However, the proportion is much lower in het-
erozygotes with variant forms. It can also be used in males as
a surrogate marker to evaluate the response to ERT [31].
Mass spectrometric proﬁling of Gb-3 isoforms may also help
to identify heterozygotes [32].
In plasma, deacylated Gb-3 (globotriaosylsphingosine,
‘lysoGb-3’) has been shown to have a better correlation with
FD. It is elevated 200–400 times in males with classical
disease, from an early phase in the disease, but its levels can
remain low in asymptomatic females or in the ‘cardiac
variant’ p.N215S in males [33–37]. The examination of the
urinary sediment with phase-contrast microscopy under po-
larized light shows tubular cells containing particles with bi-
refringent Maltese Crosses, having a lamellated appearance
with protrusions, and consisting of accumulated Gb-3. In the
hands of Selvarajah et al. [38], this was a highly sensitive and
speciﬁc tool for screening of FD, but its accuracy is strongly
operator-dependent and therefore, it is probably an unrealis-
tic option for large-scale screening studies.
WORK-UP OF A PATIENT WITH FD
3.1 We recommend that the detailed baseline and follow-up
data of all patients with established FD should be trans-
ferred to a central registry. (Ungraded statement)
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3.2 We recommend baseline and subsequent yearly evalu-
ation by a multidisciplinary team, including kidney func-
tion and albuminuria, in all patients with established FD
(cardiology, neurology and nephrology). (Ungraded
statement)
3.3 We recommend not considering female carriers for living
donation, unless in exceptional cases. In these cases, we
recommend a kidney biopsy to evaluate the risk for the
donor and acceptor. (Ungraded statement)
Once an index patient is diagnosed, a baseline evaluation is
indicated. As FD is a progressive multisystem disease, base-
line evaluation is optimally performed by a multidisciplinary
team (Table 1, adapted from Eng et al. [39]). The baseline
evaluation should be performed in male and all female car-
riers, as the phenotype can be equally severe.
As this document is written from the nephrology perspective,
we will focus on renal involvement in what follows. For evalu-
ation and pathophysiology of other organs, we refer to the
guidelines of the respective subspecialities.
Renal involvement is a cardinal feature of FD. Gb-3 depo-
sition in renal cells is progressive and begins early in life.
Besides these deposits, pathogenic mechanisms result in
glomerular ischaemia with subsequent glomerulosclerosis and
tubular atrophy, even very early in the disease course. Vacuo-
lization of podocytes and epithelial cells is a characteristic
optical microscopy histological ﬁnding. These vacuoles are
ﬁlled with deposits on electron microscopy, or following to-
luidine blue staining of samples prepared for electron
microscopy. At an early stage, hyperﬁltration may, as in dia-
betes, be the ﬁrst sign of kidney damage.
As FD can progress subclinically, adolescent and adult
patients should have urinary albumin measurement, as this is
one of the ﬁrst signs of Fabry nephropathy. We suggest asses-
sing the amount of albumin normalized for creatinine on a
fresh morning sample as diagnostic test. We suggest measur-
ing urinary albumin rather than total protein, as it is more
sensitive. Renal function can be assessed using serum creati-
nine and eventually formulas to translate serum creatinine to
estimated clearances. Even in the absence of albuminuria or
renal failure, all these parameters should be re-evaluated at
least yearly in order to detect progressive disease.
Renal intracellular Gb-3 deposits may be present even in
young children with normal GFR and minimal or absent
micro-albuminuria. In a recent study of 14 young Fabry
patients aged 4–19 years with normal GFR, there was an
F IGURE 1 : Flowchart for screening for FD in CKD patients.
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Table 1. Proposed assessments in FD patients (reproduced with permission from Eng et al. [39])
Organ system Assessment Recommendation
General General status, school or work
performance, sports, depression,
anxiety, drug use, pedigree update,
somatic growth
Baseline (at ﬁrst visit), every 6 months
Complete physical examination SF-
36®Health Survey, or PedsQL™
Measurement Mode
Baseline, every 6 months
Genetic counselling Baseline, every 6 months for new
issues
Genotype If not previously determined
Kidney Serum electrolytes, creatinine, BUN;
24-h urine or spot urine for total
protein/creatinine, albumin/creatine,
sodium, creatinine
Baseline, every 3 months if CKD
Stage 1 or 2 and >1
g/day of proteinuria or CKD Stage 4
Every 6 months if CKD Stage 3
Every 12 months if CKD Stage 1 or 2
and <1 g/day of proteinuria
Cardiac Palpitations, angina Baseline, every 6 months
Blood pressure, rhythm Every evaluation visit
ECG, echocardiography 2D with
Doppler
Baseline, every other year for patients
≤35 years of age, every year thereafter
Holter monitoring, 30-day event
monitoring
If an arrhythmia is suspected or
palpitations are present
MRI, strain rate imaging Optional
Coronary angiography If clinical signs of angina
Neurologic Acroparesthesias, fatigue, fever,
sweating, heat and cold intolerance,
joint pains, stroke-related symptoms,
TIA
Baseline, every 6 months
Neurologic exam, Brief Pain or
McGill Pain Inventory
Baseline, every 6 months
Brain MRI without contrast Baseline, at the time of a TIA or
stroke event or in females to
document CNS involvement
Magnetic resonance angiography If cerebral vasculopathy should be
excluded
Cold and heat intolerance, pain,
vibratory thresholds, sweat output,
post-ganglionic sudomotor function,
superﬁcial skin blood ﬂow
When available
Co-morbid stroke risk factors:
cholesterol (Total, LDL, HDL),
triglycerides
Annually
Lipoprotein A, total plasma
homocysteine, factor V Leiden
(G1691A), Protein C, Protein S,
prothrombin G20210A, antithrombin
III, abticardiolipin antibody, lupus
anticoagulant
At baseline, single assessment
Continued
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association between the volume of Gb-3 deposition in the po-
docytes, and age. The volume of Gb-3 deposition was also
correlated with urinary protein excretion rates [40]. Tøndel
et al. [41] found segmental foot process effacement in all
young Fabry patients, despite the fact they were normo-albu-
minuric (below 30 mg/day). Thus, in the case of patients at
risk of FD, any albuminuria, even if in the ‘normal’ range,
should be considered as suspect.
Proteinuria progresses and correlates with and probably also
contributes to the decline in renal function, e.g. male Fabry
patients with a proteinuria >1 g/24 h had a greater yearly
decline in renal function (−6.9 mL/min/1.73 m2) than patients
with proteinuria between 0.1 and 1 g/24 h (−2.2 mL/min/1.73
m2) and patients with proteinuria <0.1 mg/24 h (−0.6 mL/min/
1.73 m2) [42]. Other studies conﬁrm that the urinary protein to
urinary creatinine ratio (UP/Cr) is the most important indicator
of renal disease progression [43]. The yearly decline in renal
function also correlates with GFR at presentation (in males, −3
mL/min/1.73 m2 with GFR >60 mL/min/1.73 m2 versus –6.8
mL/min/1.73 m2 with GFR≤ 60 mL/min/1.73 m2; in females
−0.9 mL/min/1.73 m2 versus− 2.1 mL/min/1.73 m2) [42].
Most patients with CKD Stages 3–5 have some degree of
proteinuria [23]. Proteinuria in the nephrotic range (>3.5 g/
24 h) is, however, rarely seen (maximal 18% in [12]).
CKD Stage 5 usually develops between the third and the
ﬁfth decade, with a mean age at diagnosis of 38, but can
appear as early as at the age of 16 [44, 45]. Interestingly, the
mean age at initiation of RRT is similar for males and
females, although the proportion of male versus female FD
patients on RRT was 9 to 1 [42].
Living related donation in FD can pose a problem if ap-
parently asymptomatic female carriers consider donating a
kidney. Even in the case of a normal renal function and in
the absence of albuminuria, signiﬁcant Gb-3 deposits can be
abundant in a renal biopsy [46] and thus female carriers are,
in our opinion, not eligible for living kidney donation.
The Fabry population is small and heterogeneous which
makes it difﬁcult to study its natural course and to conduct
larger-scale, placebo-controlled or open-label clinical trials.
For these reasons, a high quality registry with all treated and
untreated patients on a European scale, developed indepen-
dently of industry, is highly desirable.
TREATMENT OF FABRY NEPHROPATHY
4.1 We do not recommend starting ERT in patients with pro-
teinuria [protein-to-creatinine ratio >1 g/g (>0.1 = gram/
mol) creatinine] or eGFR <60 mL/min/1.73 m2, except
for non-renal indications. (1D)
4.2 We recommend that when ERT is deemed indicated, it
should be started as part of a well-designed clinical trial,
either observational or interventional. (Ungraded
statement)
Table 1. Continued
Organ system Assessment Recommendation
ENT Tinnitus, hearing loss, vertigo,
dizziness
Baseline, every 6 months
Audiometry, tympanometry,
otoacoustic emissions
Baseline, and yearly thereafter
Ophthalmologic Visual disturbances, light sensitivity Baseline, every 6 months
General pohtalmologic exam (slit-
lamp, direct ophtalmoscopy, best
corrected visual acuity, visual ﬁelds)
Baseline, every 12 months
Retinal disfunction testing (ERG,
colour vision testing, visual-evoked
potentials, retinal angiography), tear
secretion testing
If clinically indicated
Pulmonology Cough, exertional dyspnoea,
wheezing, exercise intolerance
Baseline, every 6 months
Spirometry, including response to
bronchodilators, treadmill exercise
testing, oximetry, chest X-ray
Baseline, every 2 years or more
frequently for clinical indications
Gastrointestinal Postprandial abdominal pain,
bloating, diarrhoea, nausea, vomiting,
early satiety, difﬁculty gaining weight
Baseline, every 6 months
Endoscopic or radiographic
evaluations
If symptoms persist or worsen despite
treatment
Skeletal Bone mineral density Baseline
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4.3 In a patient on haemodialysis, and when ERT is deemed
indicated, we recommend administering the ERT during
a haemodialysis session. (1A)
4.4 We recommend kidney transplantation as a valuable
option in patients who are eligible for this intervention.
(Ungraded statement)
4.5 After renal transplantation, we do not suggest ERT for
renal indications, but it can be continued for non-renal
indications. (Ungraded statement)
As discussed above, proteinuria is an important risk factor
for the progression of renal FD. The use of ACE-i and ARB
has been shown to be nephro-protective in other proteinuric
renal diseases, and could thus be important in FD as well. As
such, the use of ACE-i or sartane would be acceptable in FD.
In a recent paper [47], it has been demonstrated that ERT
interacts with ACE and inhibits its activity, possibly by re-
moving the galactose residues from the enzyme. The clinical
relevance of this observation is unclear, and should not be
seen as a reason to prohibit the use of ACE-i.
Kidney Disease Improving Global Outcomes (KDIGO)
guidelines suggest that in patients with CKD Stages 3–5,
vitamin D deﬁciency be corrected [48]. Emerging evidence in
patients with CKD show that vitamin D can reduce protei-
nuria or albuminuria even in the presence of angiotensin-
converting enzyme inhibition [49]. Selective activation of the
vitamin D receptor with paricalcitol lowered urinary albumin
excretion, as was demonstrated in patients with Type 2 dia-
betes in a recent randomized controlled trial [50]. In cultured
human podocytes, vitamin D receptor activation prevented
lyso-Gb-3-induced, TGFβ1-mediated, up-regulation of extra-
cellular matrix proteins [51]. Even lacking more deﬁnitive
evidence of a beneﬁcial effect of vitamin D on Fabry nephro-
pathy, it seems advisable to place particular emphasis in fol-
lowing guidelines on vitamin D management in CKD
patients in patients with FD.
Two forms of recombinant α-Gal A have been approved
in Europe: agalsidase alpha (Replagal®; Shire Human Genetic
Therapies, Boston, MA) and agalsidase beta (Fabrazyme®;
Genzyme, Cambridge, MA). Agalsidase alpha is produced in
a continuous human cell line and is administered as an intra-
venous infusion over 40 min at a dose of 0.2 mg/kg body
weight every 2 weeks. Agalsidase beta is produced in Chinese
hamster ovary (CHO) cells and is given as an intravenous in-
fusion over a 4-h period at a dose of 1.0 mg/kg body weight
every 2 weeks.
According to a recent Cochrane review, the evidence base
in favour of ERT is weak. Only ﬁve (total n = 187) poor
quality randomized controlled trials are available. They all
concern surrogate end points, such as decrease in plasma Gb-
3 levels in plasma and tissues and evolution of renal function.
According to the Cochrane review, these studies show no evi-
dence for a clinical beneﬁt of the use of agalsidase alpha or
beta to treat Fabry nephropathy [52]. As there are at present
no hard data that ERT alters the natural course of Fabry ne-
phropathy (Table 2), we recommend starting ERT only in the
context of a clinical trial, interventional or observational. All
data from observational trials should be entered in a central
registry.
Besides randomized controlled trials open-label studies
and retrospective analyses have been performed. It is of inter-
est to compare the evolution of renal disease in the historical
untreated and treated cohorts of an international industry
sponsored registry on FD [43, 53]. It is difﬁcult to compare
the data presented in both publications, as the design of the
analyses and the presentation of data were different, and
there was a substantial risk for selection bias, as only a minor
proportion of all those enrolled could be evaluated because of
missing data. Nevertheless, in both studies, patients were stra-
tiﬁed into quartiles according to severity indices of renal in-
volvement. The slope of change in GFR was similar in
comparable quartiles of the treated and untreated cohorts,
especially in men. Hence, one cannot deny the reﬂection that
ERT might have no marked impact on the decline of kidney
function. From this comparison, it is also clear that, irrespec-
tive of ERT, proteinuria was the strongest predictor of
outcome. In patients without proteinuria, renal function re-
mained stable, equally in males as in females. In those with
proteinuria, the slope of deterioration of eGFR appeared to
be similar with or without ERT. It is unclear what the impli-
cations of these observations are with regard to ERT: either it
implies that ERT should be given before proteinuria develops
(but these subjects have no deterioration of kidney function
anyway) or that it should not be given for renal protection in
those with already existing heavy proteinuria. It would be in-
teresting to include complete data sets in a registry of patients
developing proteinuria at early stages to see how the evol-
ution of renal function is in this cohort. Remarkably, in the
Fabry Registry, data on proteinuria were available in only 462
of 2850 (historical cohort) and 213 of 2887 (ERT cohort)
patients [43].
Other observational studies in male FD patients showed
that renal function remained stable under ERT during a
follow-up period up to 54 months in the case of normal or
near normal baseline function (CKD 1–2) and low protei-
nuria (<1 g/g creatinine) in the majority of patients [54].
However, as only treated patients were observed, it cannot
be excluded that these patients would have had no pro-
gression even without therapy, as it is clear from registry
data that proteinuria <0.3 g/g creatinine is a favourable
prognostic marker. Other publications demonstrate that in
FD patients with CKD Stage 4, or with glomerulosclerosis
>50% or proteinuria >1 g/g creatinine, renal function con-
tinues to deteriorate despite ERT (decline in renal function
varying from 6.4 to 8.9 mL/min/1.73 m2/year [54, 55]. In
the case of CKD Stage 3, the decline in eGFR seems to be
attenuated by ERT in comparison with historical data [−3.0
(male) and −1.0 versus −6.8 mL/min/1.73 m2/year) [56].
Again, these data are small-scaled and use historic data as
controls.
Few studies report on the effect of ERT on renal function
in females. In a recent retrospective study of the Fabry
Outcome Survey (FOS), the rate of decline in eGFR in
females under ERT was similar to the normal expected age-
related rate over a 4-year follow-up period, whereas the rate
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in men was approximately double the expected age-related
rate of decline [57]. Another study reported on a stable renal
function in female patients treated with ERT [58].
In summary, these studies suggest that, for the renal
aspect of FD, treatment is at best only effective in CKD Stage
1 or 2, before the deterioration of renal function or onset of
overt proteinuria, as it does not reduce proteinuria per se.
Once proteinuria (>1 g/day) or CKD Stage 3 (eGFR <60 mL/
min/1.73 m2) develops, there are no data supporting a poten-
tial protective effect of ERT. Taking this and the very high
cost (>200 000 Euro/year) into account, we do not rec-
ommend treatment in these cases.
ERT has few side effects, except for mild infusion-related
reactions consisting primarily of chills that can be treated
with paracetamol, antihistamines or steroids. It has been
shown that the infusions can be safely performed in a home
setting [59, 60].
The administration of ERT leads to the formation of anti-
bodies in the majority of patients, and this is for both brands.
These antibodies, especially the IgG, have inhibitory effects
Table 2. Randomized controlled trials in ERT; data concerning the kidney, reproduced from Dib
et al. [52]
Comparison I:
Agalsidase alpha
versus placebo
Agalsidase alpha
(n)
Mean (SD) Placebo (n) Mean (SD) Mean difference,
95% CI
Urinary sediment Gb3
Schiffmann 2001
up to 6 months
14 1683 (1657) 11 2495 (1104) −812,00
(−1897.83,
273.83)
Kidney Gb3
Schiffmann 2001
up to 6 months
14 15.6 (5.98) 11 18.1 (10.54) −2.5 (−9.47,
4.47)
Creatinine clearance
Schiffmann 2001
up to 6 months
13 94.8 (27.76) 11 84.5 (35.15) 10.30 (−15.37,
35.97)
Insulin clearance
Schiffmann 2001
up to 6 months
13 71 (16.11) 11 71.5 (32.03) −0.50 (−21.36,
20.36)
Mesangial widening
Schiffmann 2001
up to 6 months
12 25.7 (20.78) 9 40.4 (28.5) −14.70 (−36.72,
7.32)
Glomeruli with segmental sclerosis
Schiffmann 2001
up to 6 months
12 6.8 (8.66) 9 3 (5.7) 3.80
(−2.35, 9.95)
Obsolescent glomeruli
Schiffmann 2001
up to 6 months
12 19.5 (20.78) 9 13 (15.3) 6.50 (−8.93,
21.93)
Comparison II:
Agalsidase beta
versus placebo
Agalsidase beta
(n)
Mean (SD) Placebo (n) Mean (SD) Mean difference,
95% CI
Renal microvascular endothelial deposits
Eng 2001 up to
6 months
29 0.4 (0.7) 29 2.1 (0.8) −1.7 (2.09,
−1.31)
Renal events
Banikazemi 2007
intention-to-
treat
10/51 7/31 13 (15.3) 0.87 (0.37, 2.04)
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on the enzyme activity in vitro [5, 6, 61, 62]. Although both
agalsidase alpha and agalsidase beta have been associated
with IgG formation, the reported incidence of antibodies has
generally been higher for agalsidase beta [62]. In a study in
134 males and females, there was no correlation between anti
α-Gal A IgG titres and the onset of clinical events or the rate
in change in estimated GFR during treatment. However, a
statistically signiﬁcant association was found between anti-α-
Gal A IgG titers and Gb-3 deposition in the dermal capillary
endothelial cells during treatment, suggesting that Gb-3 clear-
ance could be impaired [63]. In another study, there was less
normalization of urinary Gb-3 in the seropositive patients
compared with the seronegative ones [64, 65].
Analysing the consequences of antibodies is challenging
because the assays are not uniform and there are no inter-
national antibody standards. Currently, numerous labora-
tories are performing α-Gal A-antibody testing. Potential
differences between antibody assays and their respective sen-
sitivities make comparison of titre values across the Fabry
community difﬁcult. The objective of the Fabry Antibody
Standardization Initiative is to identify differences in analyti-
cal methods and to standardize α-Gal A antibody assays
across the industry to allow the medical community involved
in treatment to interpret antibody data equally [66].
We have very few data on the efﬁciency of higher doses
than the ones registered for agalsidase alpha (0.2 mg/kg
EOW) and agalsidase beta (1 mg/kg EOW). One open-label
trial studied 11 adult male patients with FD who demon-
strated a continuing decline in renal function despite 2–4
years of conventionally dosed agalsidase alpha therapy (0.2
mg/kg EOW) [67]. After switching to weekly dosing, three
patients demonstrated an improvement in eGFR and six
patients demonstrated a slow down in the rate of eGFR
decline. Two patients failed to improve their eGFR slope. A
multiple regression model conﬁrmed that the weekly infusion
regimen was the strongest explanatory variable for the change
in eGFR, with a weaker contribution from the concomitant
use of angiotensin-converting enzyme inhibitors/ARB, but
the patient number was too low to allow meaningful
conclusions.
We also have very few data comparing the two formulas.
In a study by Vedder et al. [65], the low number of patients
and the dose of agalsidase beta that was used (0.2 mg/kg
instead of the licensed 1.0 mg/kg) precluded ﬁrm con-
clusions. In a larger group of patients (n = 146), there was no
difference in a composite outcome of renal, cardiac and
neurological events after 30 months of treatment (West, Mol-
ecular Genetics and Metabolism, 2011, abstract).
Tahir et al. found stabilization of renal function in a small
open-label observational study in patients with CKD Stage 1–
2 (n = 4) and CKD Stage 3–4 (n = 6) treated with a combi-
nation of agalsidase beta 1 mg/kg EOW and ACEi or ARB.
The surprisingly favourable response in patients with GFR
<60 mL/1.73 m2/min and proteinuria >1 g/day was unex-
pected and should be conﬁrmed in a larger study [68]. It is
unclear in how far the positive effect, when conﬁrmed,
should be attributed to the ACE-i or the ERT. There is an
on-going open-label, prospective, multi-centre study [The
Fabrazyme® and ARB’s and ACE Inhibitor Treatment
(FAACET) Study, registered at ClinicalTrials.gov
NCT00446862], with as primary hypothesis that titration of
ACEi and ARBs to reduce urine protein excretion to <500
mg/day in Fabry patients receiving agalsidase beta therapy at
1 mg/kg every 2 weeks will slow the progression rate of
decline of GFR compared with case–controls drawn from a
Genzyme-sponsored Phase III extension study (GFR 60–125
mL/min/1.73 m2, urine protein >1 g/day) or the Phase IV
study (GFR 20 to 60 mL/min/1.73 m2, urine protein >0.5 g/
day).
Survival of Fabry patients on RRT is poor, with a reported
3-year survival of 60–63%, which is lower than that of non-
diabetic-matched controls [69]. There is no proof of an im-
proved survival in RRT patients on ERT.
In patients with CKD Stage 5, where ERT is deemed to be
an appropriate option, ERT can be performed during the
haemodialysis sessions, which do not alter pharmacokinetics
[70].
ERT diminished extra renal symptoms, and improved
quality of life and in CKD Stage 5 patients on dialysis in a
small (n = 9), non-placebo controlled cross-sectional study
[71]. In another observational cross-sectional study (n = 16)
on dialysis patients, with a mean follow-up of 45 months of
ERT, mortality was very high (7/11), when patients were not
transplanted [72]. These limited data suggest that, although
typical Fabry symptoms such as pain crises can be controlled
with ERT, we have no proof of improvement of cerebrovascu-
lar or cardiac morbidity or mortality in CKD Stage 5. Instead,
mortality remains high if these patients are not transplanted.
Transplantation without ERT has shown acceptable results.
In a retrospective study, patient and graft survival was good
for the ﬁrst 10 years, although this study was probably under-
taken in a selected patient group with little co-morbidity.
After 10 years, mortality increases very quickly, probably due
to progression of FD [73]. Data from the organ procurement
Transplant Network/United Network for Organ Sharing
(n = 197) were compared with a matched cohort of non-
Fabry and non-diabetic CKD Stage 5 patients; although 5-
year graft survival was similar, Fabry patients had a higher
risk of death [RR 2.15 (1.52–3.02)] [74]. All these data seem
to indicate that transplantation can be successful in patients
with Fabry nephropathy, and that transplanted patients have
a stable kidney function without ERT.
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